KTTA

Pasithea Therapeutics Corp. (NASDAQ:KTTA) is a clinical-stage biotechnology company founded in 2020 and headquartered in Miami Beach, Florida. The company went public in September 2021 and focuses on developing treatments for psychiatric and neurological disorders. Pasithea operates as a pre-revenue biotech company conducting research and discovery activities while also planning to establish anti-depression treatment clinics that would offer ketamine infusion therapies administered by trained pharmacists.